EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Sarah C Rutherford iD, Hongli Li iD, Alex F Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison iD, Susan K Parsons iD, Joseph M Unger iD, Anamarija M Perry, Carla Casulo iD, Nancy L Bartlett iD, Joseph M Tuscano und 11 weitere

Journal of Clinical Oncology · 20.09.2025 · 43 (27) · 2968-2973

DOI: 10.1200/jco-25-00204 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.09.2025. Verfasst von Sarah C Rutherford und 22 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Hodgkin Disease, Nivolumab. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three S1826 trial conducted by SWOG that randomly assigned patients with newly diagnosed advanced-stage (III-IV) cHL to six cycles of nivolumab (N)–AVD or brentuximab vedotin (BV)–AVD. Of 103 enrolled patients 60 years and older, 99 were eligible. At a median follow-up of 2.1 years, the 2-year progression-free survival was 89% after N-AVD (n = 50) and 64% after BV-AVD (n = 49, HR 0.24, 95%CI 0.09-0.63, 1-sided stratified log-rank P = .001). The 2-year OS was 96% with N-AVD versus 85% with BV-AVD (HR 0.16, 95%CI 0.03-0.75 stratified 1-sided log-rank P = .005). Six cycles were delivered without dose reduction in 69% on N-AVD and 26% on BV-AVD; 55% discontinued BV, and 14% discontinued nivolumab. The nonrelapse mortality was 16% with BV-AVD and 6% with N-AVD. Despite more neutropenia with N-AVD, febrile neutropenia, sepsis, and infections were higher with BV-AVD, as was peripheral neuropathy. Patient-reported outcomes of key adverse events confirmed the improved toxicity profile of N-AVD over BV-AVD. N-AVD was better tolerated and more effective than BV-AVD and is therefore a new standard of care for older patients with advanced-stage cHL fit for anthracycline-based combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinHodgkin DiseaseNivolumabAgedAged, 80 and overFemaleHumansMaleMiddle AgedAge FactorsNeoplasm StagingProgression-Free Survival

Substanzen

Brentuximab VedotinNivolumab

Autor:innen und Institutionen

  • Weill Cornell Medicine, New York, NY.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada.
  • Tufts Medical Center, Boston, MA.

ORCID-Profile: Sarah C Rutherford, Hongli Li, Kelly Davison, Susan K Parsons, Joseph M Unger, Carla Casulo, Nancy L Bartlett, Pallawi Torka, Pankaj Kumar, Joo Y Song, Sharon M Castellino, Brad Kahl, Andrew M Evens

Förderung

  • NCI NIH HHS

Zitieren

APA

Rutherford, S. C., Li, H., Herrera, A. F., LeBlanc, M., Ahmed, S., Davison, K., Parsons, S. K., Unger, J. M., Perry, A. M., Casulo, C., Bartlett, N. L., Tuscano, J. M., Hess, B. T., Torka, P., Kumar, P., Jacobs, R., Song, J. Y., Castellino, S. M., Kahl, B., …, & Evens, A. M. (2025). Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. Journal of Clinical Oncology, 43(27), 2968-2973. https://doi.org/10.1200/jco-25-00204

Vancouver

Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, et al. Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. Journal of Clinical Oncology. 2025;43(27):2968-2973. doi:10.1200/jco-25-00204

BibTeX
@article{Rutherford2025,
  author = {Rutherford, Sarah C and Li, Hongli and Herrera, Alex F and LeBlanc, Michael and Ahmed, Sairah and Davison, Kelly and Parsons, Susan K and Unger, Joseph M and Perry, Anamarija M and Casulo, Carla and Bartlett, Nancy L and Tuscano, Joseph M and Hess, Brian T and Torka, Pallawi and Kumar, Pankaj and Jacobs, Ryan and Song, Joo Y and Castellino, Sharon M and Kahl, Brad and Leonard, John P and Smith, Sonali M and Friedberg, Jonathan W and Evens, Andrew M},
  title = {Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {27},
  pages = {2968--2973},
  doi = {10.1200/jco-25-00204}
}
Kostenlos starten →